$AIM announced that it has entered into a clinical trial agreement with Roswell Park Comprehensive Cancer Center to support Roswell Park's Phase 1/2a trial of Ampligen  in combination with interferon alfa-2b, in cancer patients with COVID-19

#daytrading #stocks